KEY POINTS
  • CNBC's Jim Cramer reveals how Bausch Health has put together an amazing comeback.
  • The "Mad Money" host also sits down with the CEO of Zebra Technologies.
  • In the lightning round, Cramer gives a bad review to the Netflix of China.

In an uncertain investing environment, CNBC's Jim Cramer likes to highlight "the best of the best" of the "slowdown plays," or stocks that do well in a weaker economy.

So, on Tuesday, the "Mad Money" host profiled the turnaround at Bausch Health Companies, the drugmaker formerly known as Valeant Pharmaceuticals. Under the leadership of Chairman and CEO Joe Papa, Bausch has undergone what Cramer said "may be the greatest turnaround story of this particular era."